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Objectives: In multiple sclerosis (MS), magnetic resonance imaging (MRI) is a sensitive tool for detecting white matter
lesions, but its diagnostic specificity is still suboptimal; ambiguous cases are frequent in clinical practice. Detection of peri-
venular lesions in the brain (the “central vein sign”) improves the pathological specificity of MS diagnosis, but comprehen-
sive evaluation of this MRI biomarker in MS-mimicking inflammatory and/or autoimmune diseases, such as central nervous
system (CNS) inflammatory vasculopathies, is lacking. In a multicenter study, we assessed the frequency of perivenular
lesions in MS versus systemic autoimmune diseases with CNS involvement and primary angiitis of the CNS (PACNS).
Methods: In 31 patients with inflammatory CNS vasculopathies and 52 with relapsing–remitting MS, 3-dimensional T2*-
weighted and T2–fluid-attenuated inversion recovery images were obtained during a single MRI acquisition after gadolin-
ium injection. For each lesion, the central vein sign was evaluated according to consensus guidelines. For each patient,
lesion count, volume, and brain location, as well as fulfillment of dissemination in space MRI criteria, were assessed.
Results: MS showed higher frequency of perivenular lesions (median588%) than did inflammatory CNS vasculopathies
(14%), without overlap between groups or differences between 3T and 1.5T MRI. Among inflammatory vasculopathies,
Behc¸et disease showed the highest median frequency of perivenular lesions (34%), followed by PACNS (14%), antiphospholi-
pid syndromes (12%), Sj€ogren syndrome (11%), and systemic lupus erythematosus (0%). When a threshold of 50% perivenular
lesions was applied, central vein sign discriminated MS from inflammatory vasculopathies with a diagnostic accuracy of 100%.
Interpretation: The central vein sign differentiates inflammatory CNS vasculopathies from MS at standard clinical
magnetic field strengths.
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Multiple sclerosis (MS) is characterized by recurrentneurological symptoms beginning in young adult-
hood, associated with focal lesions scattered in the central
nervous system (CNS).1 Pathologically, white matter
(WM) lesions correspond to inflammatory infiltrates that
develop around venules.2,3 These infiltrates (widely
known as perivascular cuffs) mainly comprise mononu-
clear cells that dynamically accumulate, distribute, and
evolve in the CNS following recurrent waves of invasion
from peripheral blood.4
The CNS of young adults may also be targeted by
chronic inflammatory vasculopathies. When these vascu-
lopathies involve small vessels, they can result in a range
of “MS-like” chronic neurological symptoms and syn-
dromes, characterized by relapsing–remitting or progres-
sive course.5,6 The parenchymal WM lesions associated
with these neurological phenotypes can be visualized by
magnetic resonance imaging (MRI) and frequently meet
the topographic MRI diagnostic criteria of MS,7 which
cannot distinguish the underlying pathology of the
lesions.8,9 When such cases occur in the context of sys-
temic inflammatory or autoimmune diseases (SADs), MS
is excluded on the basis of the diagnostic criterion of
“better explanation.”7 However, an acute neurological
syndrome can be the first clinical presentation in SADs,
and sometimes MS and SAD can coexist in the same
patient.10 In all these cases, differentiation from MS may
be problematic, and a “better explanation” of the diagno-
sis cannot be invoked.11,12 In addition, the current stan-
dard for diagnosis of inflammatory vasculopathies is
brain/meningeal biopsy or angiography,11,12 but these,
unlike MRI, are substantially invasive procedures and are
not always diagnostic.13
The physical relationship between WM lesions and
venules can now be visualized by susceptibility-based
MRI sequences, taking advantage of the T2*-shortening
effect of deoxyhemoglobin14,15 in venous blood.16 Several
studies conducted with 3T and 7T MRI clearly showed
that in MS, the association between brain WM venules
and lesions (perivenular lesions), also named the “central
vein sign,”17 can be efficiently visualized; in MS, the pro-
portion of lesions that have clear central veins is
high.14,15 These data suggest that high frequency of peri-
venular lesions is pathologically specific to MS, and
therefore this marker is an important candidate for
improving MRI diagnostic criteria14 and for reducing the
still too high rate of MS misdiagnosis, with its consider-
able clinical consequences.18,19
Thus far, the central vein sign has been compared
primarily between MS and a limited set of other neuro-
logical diagnosis, such as migraine and ischemic small
vessel disease of the elderly,20,21 which do not involve
inflammation or autoimmunity similar to MS.11,12
Proper validation of an MRI marker to improve differen-
tial diagnosis between MS and other MS-like neurologi-
cal syndromes in young adults requires comparison with
other inflammatory diseases with CNS involvement.
Thus, in this study, the frequency of brain WM perive-
nular lesions visualized by MRI was compared between
MS and SADs, encompassing Behc¸et disease, systemic
lupus erythematosus (SLE), antiphospholipid syndrome




Eigthy-three consecutive patients diagnosed with either SADs
and clinical/MRI evidence of brain involvement, or with
PACNS (hereafter both termed “inflammatory vasculopathies”),
or with relapsing–remitting MS according to the 2010 McDo-
nald revised criteria,7 were recruited between January 2015 and
June 2017 at 4 academic research hospitals: the Careggi Univer-
sity Hospital (Florence, Italy), the Erasme University Hospital
and Brugmann University Hospital (Brussels, Belgium), and the
San Raffaele University Hospital (Milan, Italy). The study
received approval from ethical standards committees on human
experimentation at all centers. Written informed consent was
obtained from all participants.
Patients were excluded if contraindicated for MRI or
intravenous injection of gadolinium-based contrast material. To
avoid problems related to assignment of central veins, patients
with extremely high lesion loads (>100 lesions) as well as
patients with diffuse leukoencephalopathy with no or few dis-
crete lesions were excluded a priori based on previously avail-
able MRI.
Included patients with inflammatory vasculopathies
encompassed: (1) SLE, diagnosed according to the Systemic
Lupus International Collaborating Clinics classification crite-
ria22; (2) APS, diagnosed according to the Miyakis criteria23;
(3) Behc¸et disease, diagnosed according to the International
Study Group for Behc¸et’s Disease24; (4) Sj€ogren disease, diag-
nosed according to the American College of Rheumatology/
European League against Rheumatism criteria25; and (5)
PACNS (imaging or biopsy proven), diagnosed according to
Schuster et al.13
MRI Acquisition Protocol
All patients underwent a single brain MRI acquisition. MRI
studies were performed on two 3T Philips (Best, the Nether-
lands) Intera MRI scanners (Brussels and Milan) and a 1.5T
Philips Achieva MRI scanner (Florence). For all scans, 3-
dimensional (3D) T2*-weighted echo-planar imaging (EPI) and
3D T2–fluid-attenuated inversion recovery (FLAIR) images
were acquired during or after intravenous injection of a single
dose (0.1mmol/kg) of gadolinium-based contrast material, as
previously described.26 3D T2*-weighted EPI and 3D T2-
FLAIR sequences were identical for the 3T scanners in Brussels
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and Milan, but adapted and optimized for the 1.5T scanner in
Florence, as previously described (Table 1).27 Additional routine
magnetic resonance images were acquired for clinical use,
including T1-weighted sequences.
MRI Postprocessing and Analysis
Four neurologists, with research training experience in MS imaging
and training in central vein sign assessment according to the con-
sensus criteria of the North American Imaging in Multiple Sclero-
sis (NAIMS) Cooperative,14 analyzed the data blinded to the
diagnosis. Two of them worked on 3T data (P.M., M.A.) and 2 on
1.5T data (L.V., M.G.). Data were collected as DICOM images
and processed and visualized using Medical Image Processing,
Analysis, and Visualization (MIPAV; NIH; http://mipav.cit.nih.
gov). FLAIR* images were generated with the following steps26:
(1) coregistration between T2-FLAIR and T2* images, (2) upsam-
pling of the T2-FLAIR image to match the T2* resolution, and
(3) voxelwise multiplication.
For the central vein sign assessment, only discrete brain
lesions with a diameter of 3mm in at least 1 plane were
included in the analysis. Small (<3mm), confluent, and poorly
visible lesions were excluded. On T2* and FLAIR* images,
lesions were defined as “perivenular” by raters’ consensus agree-
ment (2 reviewers for 3T and 2 reviewers for 1.5T MRI data),
according to the NAIMS guidelines,14 as follows: “(1) the
lesion contains a thin hypointense line (<2mm diameter) or
small hypointense dot that is visible in at least two
perpendicular MRI planes; and (2) the vein, running partially
or entirely through the lesion, appears as positioned approxi-
mately in the center of the lesion.” Lesions that did not meet
these criteria were considered nonperivenular. The frequency of
perivenular lesions per patient was expressed as a percentage of
the total number of analyzed lesions.
For each patient, additional lesion morphological features
were recorded: (1) brain location (periventricular, juxtacortical/
leukocortical, subcortical/deep WM, or infratentorial), (2)
lesion volume (manual segmentation using MIPAV), and (3)
gadolinium enhancement.
Finally, for each patient, fulfillment of MS MRI criteria
for dissemination in space was assessed, respectively, according
to Polman et al7 and Filippi et al.28 We dichotomized patients
as overall perivenular positive versus perivenular negative based
on the highest frequency of perivenular lesions observed in the
vasculopathy group. Similarly, we also dichotomized patients
based on 3 previously published suggested criteria: (1) the
“40% rule,” whereby a threshold of 40% perivenular lesions
distinguishes MS from non-MS17; (2) the “6-lesion rule,”
whereby 10 lesions are randomly assessed and MS is diagnosed
if at least 6 lesions are perivenular20; and (3) the “3-lesion
rule,” whereby 3 lesions are randomly assessed and MS is diag-
nosed if these 3 lesions are perivenular.29
Statistical Analysis
Demographic, clinical, and MRI differences in patients with
inflammatory vasculopathies versus MS were assessed with
Mann–Whitney U test and Fisher exact test, when appropriate.
Mean differences in lesion location proportion between groups
were assessed with a 2-way repeted measures analysis of variance
with interaction, where brain lesion location was the within-
subject factor and group was the between-subject factor; probabil-
ity values were adjusted for post hoc comparisons (Bonferroni).
Results
Clinical Data
Clinical and demographic characteristics of inflammatory
vasculopathy (n5 31) and relapsing–remitting MS
(n5 52) patients are reported in Table 2. The 2 groups
were comparable for sex and disease duration. As
expected, in patients with inflammatory vasculopathies,
there was a higher frequency of seizures, systemic vascular
events/stroke, and headache (Fisher exact test,
p< 0.0001). Cerebrospinal fluid data were available in
10 of the 31 inflammatory vasculopathy cases and in 47
of 52 MS cases; as expected, oligoclonal bands were
more frequently detected in MS patients (see Table 2).
None of the patients with inflammatory vasculopathies
presented with spinal cord (or optic nerve) syndromes or
with radiological signs typical of neuromyelitis optica
(NMO) spectrum disorder (NMOSD). NMO IgG was
tested in 1 of these patients (a case of Sj€ogren disease),
resulting negative.
TABLE 1. MRI Sequence Parameters of 1.5T and
3T MRI Scanners
Sequence
3D T2*-EPI 3D T2-FLAIR
Magnet strength, T 1.5 3 1.5 3
Manufacturer Philips Philips Philips Philips
Model Achieva Intera Achieva Intera
Receive channels 8 8 8 8
Imaging plane Sagittal Sagittal Sagittal Sagittal
Imaging
resolution, mm
0.8 0.55 1 1
Slices, No. 200 336 180 180
Repetition time, ms 41 53 4,800 4,800
Echo time, ms 22 29 297 373
Inversion time, ms — — 1,660 1,600
Flip angle 10 8 10 8 90 8 90 8
Averages 2 2 1 1
Acquisition time, min:s 4:24 4:40 5:55 6:00
3D5 3-dimensional; EPI5 echo-planar imaging; FLAIR5 fluid-
attenuated inversion recovery; MRI5magnetic resonance imaging.
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Lesion Counts and Brain Location
The median number of brain WM lesions per patient
did not differ between inflammatory vasculopathies and
MS patients (median number5 15, range5 1–93 vs
median number5 15, range5 2–66, respectively; Mann–
Whitney U test, p5 0.6), whereas the median lesion vol-
ume was 34% smaller in inflammatory vasculopathies
than in MS (122mm3, range5 15–734 vs 186mm3,
range5 29–943; Mann–Whitney U test, p5 0.048).
Fewer patients with inflammatory vasculopathies (2 of 31
patients, 6%) had contrast-enhancing lesions than MS
patients (11 of 52 patients, 21%).
The topographical distribution of brain lesions is
shown in Figure 1. As expected, a significantly higher rel-
ative frequency of subcortical/deep WM lesions was
observed in inflammatory vasculopathies than in MS
(p< 0.0001); conversely, periventricular lesions were
more frequent in MS than in inflammatory vasculopa-
thies (p< 0.0001). However, there was a great deal of
overlap between diagnostic groups. No differences in
juxtacortical/leukocortical and infratentorial lesion fre-
quency were observed between the 2 groups. The
regional lesion distribution among patients with at least
1 lesion per brain location did not significantly differ
between groups (chi-square test, p5 0.18).
Central Vein Sign Assessment
The frequency of perivenular lesions was remarkably
higher in MS (median5 88%, range5 58–100%) versus
inflammatory vasculopathies (14%, 0–50%; Mann–
Whitney U test, p< 0.0001; see Fig 1). The separation
between the 2 groups based on perivenular lesion fre-
quency was complete (>50% perivenular lesions thresh-
old, hereafter referred as the “50% rule”).
The frequency of perivenular lesions within groups
did not differ significantly between 1.5T and 3T MRI
(median5 88%, range5 67–100% and median5 85%,
range 58–100%, respectively, in MS; median5 18%,
range5 0–50% and median5 14%, range 0–40%,
respectively, in inflammatory vasculopathies).





Patients, No. 31 52 —
Median age (range) 45 (27–70) 41 (20–65) Mann–Whitney
p5 0.02
Sex, F/M 20/11 34/18 n.s.
Clinical data
Clinical diagnosis 9 SLE, 10 Behc¸et, 2 Sj€ogren,
7 APS, 3 PACNS
52 RRMS —
Median disease duration, yr (range) 10 (0.5–22) 7.7 (0.5–39) n.s.
Median EDSS (range) 1 (0–3) 2 (0–4) Mann–Whitney
p5 0.003
Median mRS (range) 1 (0–2) 1 (0–2) n.s.
MMSE< 24 0% 0% n.s.
Focal neurological symptoms 39% 67% Fisher p5 0.0001
History of seizures 29% 4% Fisher p< 0.0001
History of systemic vascular events or stroke 39% 0% Fisher p< 0.0001
History of headache 55% 12% Fisher p< 0.0001
OCB presence, No. (%) 1/10 available (10%) 46/47 available (98%) Fisher p< 0.0001
SLE= systemic lupus erythematosus; APS5 antiphospholipid antibody syndrome; PACNS5primary angiitis of the central nervous system;
RRMS5 relapsing–remitting MS; EDSS5Expanded Disability Status Scale; F5 female; M5male; MMSE5Mini-Mental State Examination;
mRS5modified Rankin Scale; n.s.5 not significant; OCB5 oligoclonal band.
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Among inflammatory vasculopathies, Behc¸et disease
showed the highest frequency of perivenular lesions
(median5 34%, range5 11–50%), followed by PACNS
(median5 14%, range5 13–31%), APS (median5 12%,
range5 0–30%), Sj€ogren (median5 11%, range5 6–
17%), and SLE (median5 0%, range5 0–16%; Figs 1–5).
When patients were dichotomized based on the 40%
rule (presence of 40% perivenular lesions),17 all MS
patients were perivenular-positive versus only 4 patients
with vasculitis (all Behc¸et disease cases; Fisher exact test,
p< 0.0001; Table 3). The 50% rule and the 40% rule
showed higher diagnostic accuracy in comparison to the 6-
lesion rule20 and the 3-lesion rule.29 Diagnostic specificity,
sensitivity, and accuracy are shown in Table 3.
Fulfillment of MRI Dissemination in Space MS
Diagnostic Criteria
Table 3 compares the fulfillment of MRI dissemination
in space MS diagnostic criteria, according to Polman
et al7 and the more recent MAGNIMS criteria (Filippi
et al).28 As a caveat, the analysis focused only on brain
lesions, neglecting the contribution of both spinal cord
(cord MRI was not available for all patients) and optic
nerve (relevant for the MAGNIMS criteria) lesions. The
addition of the 40% rule to Polman and to Filippi crite-
ria, respectively, increased the specificity, without decreas-
ing the sensitivity, of current dissemination in space MRI
criteria (see Table 3). Similarly, the addition of the 6-
lesion rule or 3-lesion rule to Polman 2011 and to
FIGURE 1: Frequency of perivenular lesions and topographical distribution of brain lesions in inflammatory vasculopathies and
multiple sclerosis (MS). APS5 antiphospholipid syndrome; PACNS5primary angiitis of the central nervous system; SLE5 syste-
mic lupus erythematosus.
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Filippi 2016 criteria, respectively, increased the specificity,
but did not dramatically change the overall diagnostic
accuracy, of current dissemination in space MRI criteria
(see Table 3).
Central Vein Sign Assessment in MS-Mimicking
Inflammatory Vasculopathies
Among the 31 patients with inflammatory vasculopa-
thies, 15 satisfied the MRI dissemination in space MS
diagnostic criteria (Polman et al7) and had no history of
previous stroke. When this MS-mimicking inflammatory
vasculopathy population was compared to the MS group,
the results were overall similar to those reported above. In
particular, the frequency of perivenular lesions in the MS-
mimicking inflammatory vasculopathy population
remained significantly lower compared to MS, maintaining
no distribution overlap between groups (median5 23%,
range5 0–50%; Mann–Whitney U test, p< 0.0001).
FIGURE 2: Representative axial 3T FLAIR* images from individuals with relapsing–remitting multiple sclerosis (MS; 27-year-old
woman), Sj€ogren disease (46-year-old woman), antiphospholipid antibody syndrome (APS; 37-year-old man), and systemic lupus
erythematosus (SLE; 38-year-old woman). The central vein sign (arrows) is present in the majority of MS lesions but is not typi-
cal of white matter lesions in inflammatory vasculopathies. Boxes show magnified views of lesions in the 3 orthogonal planes
for central vein assessment. [Color figure can be viewed at www.annalsofneurology.org]
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Discussion
The main finding of this multicenter study is that central
vein assessment, provided by susceptibility-based MRI,
significantly improves the differential diagnosis between
MS and inflammatory vasculopathies involving the CNS.
Specifically, the central vein sign alone or in combination
with available MS diagnostic MRI criteria7,28 improves
the diagnostic accuracy and specificity, without lowering
the sensitivity, of MS diagnosis. Assessments were per-
formed on standard clinical magnetic field strength sys-
tems, and results at 3T and the more widely available
1.5T were indistinguishable.
Our findings are particularly relevant considering
that CNS inflammatory vasculopathies can present with
a chronic relapsing or progressive (MS-like) clinical
course and often feature brain WM abnormalities indis-
tinguishable from those observed in MS.10 Moreover, the
diagnosis of CNS inflammatory vasculopathies remains
challenging due to the lack of well-defined diagnostic cri-
teria and to the relatively high risk and limited accuracy
of the available diagnostic techniques (biopsy and/or
angiography), especially when involvement is limited to
small vessels. Remarkably, despite some differences in
brain lesion size (usually smaller) and location (mainly
FIGURE 3: Axial, sagittal, and coronal 3T FLAIR* images from individuals with relapsing–remitting multiple sclerosis (MS; 30-
year-old woman; top) and Behc¸et disease (42-year-old woman; bottom), respectively. Perivenular MS-like lesions (arrows) can
be seen in Behc¸et disease. Magnified views of representative lesions are displayed in the boxes. [Color figure can be viewed
at www.annalsofneurology.org]
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subcortical), the two disease groups cannot be efficiently
discriminated by these radiological markers. A large pro-
portion of our inflammatory vasculopathy patients ful-
filled the dissemination in space MRI criteria for MS
(52% and 26% using Polman and Filippi 2016,
MAGNIMS criteria, respectively7,28).
What is the value of adding the central vein assess-
ment to the diagnostic workup? We found that the per-
centage of perivenular lesions was higher in every MS
case than in any of the inflammatory vasculopathy cases,
rendering the diagnostic accuracy of this marker out-
standing. However, although the previously proposed
FIGURE 4: Axial 3T FLAIR* images showing the presence of nonperivenular parenchymal lesions in 2 patients with primary angiitis
of the central nervous system (PACNS). (A) Biopsy-proven PACNS (57-year-old man; biopsy of the right frontal lobe and overlaying
leptomeninges, asterisk). The histopathology shows the presence of a vasculocentric, transmural, multilayer inflammatory infil-
trate (predominantly T lymphocytes) involving both the leptomeningeal and parenchymal arterioles. Scale bars: hematoxylin &
eosin (H&E), 100mm; CD3 (T lymphocytes), 250mm; CD68 (macrophages), 100mm; CD20 (B lymphocytes), 50 mm. (B) Imaging-
proven PACNS (48-year-old man). Vessel-wall enhancement (arrows) of the left posterior and left middle cerebral artery is demon-
strated using black-blood arterial wall magnetic resonance imaging (MRI).
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40% rule can differentiate MS from small vessel ischemic
disease with high specificity and accuracy,17 in our cohort
4 inflammatory vasculopathy patients (all with Behc¸et
disease) had 40% perivenular lesions. Based on these
results, we propose a new 50% rule for the workup of
MS versus vasculitis. In this setting, the 50% rule per-
formed better than other proposed criteria, namely the
6-lesion and 3-lesion rules,20,29 which avoid the require-
ment for analysis of every single lesion. In our cohort,
those criteria, relative to the Polman or Filippi 2016
MAGNIMS criteria for MS,7,28 had better specificity but
worse sensitivity for MS diagnosis.
Although the perivenular topography of MS lesions
is well known and is considered a pathological hallmark
of the disease, much less is known about the perivascular
nature of parenchymal WM lesions in inflammatory vas-
culopathies. The immunopathogenesis of MS lesion for-
mation is believed to follow a classical inflammatory
cascade, where primed lymphocytes and monocytes crawl
and extravasate at the venular side of the
FIGURE 5: Representative axial 1.5T T2* echo-planar images from individuals with relapsing–remitting multiple sclerosis (MS;
55-year-old and 24-year-old women), antiphospholipid antibody syndrome (APS; 51-year-old woman), and systemic lupus eryth-
ematosus (SLE; 40-year-old woman). The central vein sign (arrows) is present in the majority of MS lesions but is not typical of
white matter lesions in inflammatory vasculopathies. Boxes show magnified views of lesions in the 3 orthogonal planes for cen-
tral vein assessment. [Color figure can be viewed at www.annalsofneurology.org]
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microcirculation, perhaps due in part to lower hemody-
namic shear pressure on the venous side. As a conse-
quence, inflammatory demyelination spreads in the
parenchyma surrounding small parenchymal venules.30,31
Conversely, in both CNS-isolated and systemic inflam-
matory vasculopathies, the pathogenic mechanism of the
parenchymal WM lesions is different from MS. These
inflammatory conditions affect medium and small vessels,
usually arteries, and are pathologically characterized by
inflammatory infiltrates of the vessel wall, fibrinoid
necrosis, and thrombosis with ischemic damage of the
CNS parenchyma.32 Microthromboembolic events and
accelerated small vessel disease have also been extensively
described and are thought to contribute to chronic ische-
mic damage occurring at the arteriolar side of cerebral
microcirculation.11,33,34
In our cohort, among all the inflammatory vasculo-
pathies, patients with Behc¸et disease showed the highest
frequency of perivenular brain lesions (range5 11–50%).
This is not surprising; previous pathological observations
reported that inflammation, in Behc¸et disease, can
involve both arteries and veins and that, similarly to MS,
brain parenchymal damage can be associated with perive-
nular lymphocyte cuffing.35 Based on the limited avail-
able data, a differential diagnosis based on the presence
of perivenular lesions should be applied cautiously in
Behc¸et disease.36
Of note, the perivenular lesion frequency observed
in the subgroup of inflammatory vasculopathies fulfilling
the McDonald MRI criteria for MS7 and without any
history of stroke events, was significantly lower compared
to MS. Thus, even in this challenging clinical scenario,
the separation between the two groups based on the peri-
venular imaging biomarker remained complete. This is
particularly relevant because misdiagnosis is frequent in
this subset of patients and becomes even more frequent
when the vasculopathic process is confined to the CNS
(PACNS).5,6,9 Based on our results, we can speculate
TABLE 3. Fulfillment of Different MRI Criteria and Diagnostic Test Evaluation
Variables Inflammatory Vasculopathies,
No. (%) of Patients
Fulfilling Criteria
Multiple Sclerosis,






50% perivenular rule 0/31 (0%) 52/52 (100%) 100% 100% 100%
40% perivenular rule 4/31 (13%) 52/52 (100%) 100% 94% 95%
6-lesion rule 9/31 (29%) 44/52 (85%) 85% 71% 79%
3-lesion rule 15/31 (48%) 51/52 (98%) 98% 52% 81%
Dissemination in
space MRI criteria
Polman 20117 16/31 (52%) 49/52 (94%) 94% 48% 77%
FIlippi 201628 8/31 (26%) 47/52 (90%) 90% 74% 84%
Combined criteria
Both Polman and 40%
perivenular rule
3/31 (10%) 49/52 (94%) 94% 90% 93%
Both Filippi and 40%
perivenular rule
0/31 (0%) 47/52 (90%) 90% 100% 94%
Both Polman and 6-lesion rule 7/31 (23%) 42/52 (81%) 81% 77% 76%
Both Polman and 3-lesion rule 11/31 (36%) 48/52 (92%) 92% 64% 82%
Both Filippi and 6-lesion rule 3/31 (10%) 41/52 (79%) 79% 90% 83%
Both Filippi and 3-lesion rule 6/31 (19%) 46/52 (88%) 88% 81% 85%
MRI5magnetic resonance imaging.
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that the central vein sign may help in the clinical workup
of PACNS patients presenting with an MS-like clinical
course.
This study presents some limitations. Our analysis
was limited to the brain and did not consider the spinal
cord in the assessement of dissemination in space MRI
criteria for MS. Of note, in vivo imaging reports of the
central vein sign in the spinal cord are lacking, due in
part to the challenge of obtaining high-quality T2*-
weighted images of the cord.14 Patients with primarily
confluent lesions were excluded from the study, and
therefore it may not be possible to generalize our results
to such patients. In addition, in most of the inflamma-
tory vasculopathy patients, possible co-occurrence of
NMOSD was excluded only by the absence of typical
syndromes or MRI characteristics and not by NMO-Ig
testing. Another limitation relies on the clinical applica-
bility of the 50% rule proposed here. Although in our
cohort the diagnostic accuracy was outstanding, applying
this rule requires time-consuming lesion counting and
frequency estimation, both of which are difficult to
implement in a clinical setting. In addition, our results
concern a specific clinical setting (ie, MS vs CNS inflam-
matory vasculopathies), and the 50% rule proposed here
may apply differently in terms of diagnostic accuracy
when dealing with other specific clinical situations (inci-
dental WM lesions, small vessel disease, migraine).
In conclusion, the central vein assessment provided
by susceptibility-based MRI is a useful tool when
attempting to differentiate MS from inflammatory vascu-
lopathies involving the CNS. These latter conditions are
sometimes difficult to diagnose accurately, as they can
have clinical and radiological presentations very similar
to MS. Thus, when evaluating patients with chronic
brain inflammatory conditions, the addition of the cen-
tral vein sign assessment to the existing clinical and
radiological workup can reduce the risk of misdiagnosis
and aid therapeutic strategies. Moreover, considering the
availability of this kind of assessment at clinical field
strength (including 1.5T MRI scanners), future imple-
mentation of automated imaging postprocessing techni-
ques (ie, automated FLAIR* reconstruction and central
vein sign detection) should allow direct translation of the
central vein sign into the everyday clinical practice.
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